Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.

Hua CK, Gacerez AT, Sentman CL, Ackerman ME.

Protein Eng Des Sel. 2017 Oct 1;30(10):713-721. doi: 10.1093/protein/gzx051.

2.

B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.

Phillips M, Romeo F, Bitsaktsis C, Sabatino D.

Biopolymers. 2016 Sep;106(5):658-72. doi: 10.1002/bip.22879.

PMID:
27216712
3.

Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.

Xu X, Li Y, Gauthier L, Chen Q, Vivier E, Mariuzza RA.

Acta Crystallogr F Struct Biol Commun. 2015 Jun;71(Pt 6):697-701. doi: 10.1107/S2053230X15006755. Epub 2015 May 20.

4.

B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.

Wu MR, Zhang T, DeMars LR, Sentman CL.

Gene Ther. 2015 Aug;22(8):675-84. doi: 10.1038/gt.2015.29. Epub 2015 Apr 1.

5.

Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy.

Gutierrez-Franco J, Hernandez-Gutierrez R, Bueno-Topete MR, Haramati J, Navarro-Hernandez RE, Escarra-Senmarti M, Vega-Magaña N, Del Toro-Arreola A, Pereira-Suarez AL, Del Toro-Arreola S.

Immunobiology. 2018 Jan;223(1):57-63. doi: 10.1016/j.imbio.2017.10.012. Epub 2017 Oct 6.

PMID:
29055565
6.

Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC.

Flajnik MF, Tlapakova T, Criscitiello MF, Krylov V, Ohta Y.

Immunogenetics. 2012 Aug;64(8):571-90. doi: 10.1007/s00251-012-0616-2. Epub 2012 Apr 11. Erratum in: Immunogenetics. 2013 Jul;65(7):559.

7.

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.

Peipp M, Derer S, Lohse S, Staudinger M, Klausz K, Valerius T, Gramatzki M, Kellner C.

Oncotarget. 2015 Oct 13;6(31):32075-88. doi: 10.18632/oncotarget.5135.

8.

Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression.

Gacerez AT, Hua CK, Ackerman ME, Sentman CL.

Cancer Immunol Immunother. 2018 May;67(5):749-759. doi: 10.1007/s00262-018-2124-1. Epub 2018 Feb 16.

PMID:
29453518
9.

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O'Reilly RJ, Cheung NK.

Leukemia. 2015 Nov;29(11):2238-47. doi: 10.1038/leu.2015.125. Epub 2015 May 19.

10.

Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes.

Gray SA, Barr JR, Kalb SR, Marks JD, Baird CL, Cangelosi GA, Miller KD, Feldhaus MJ.

Biotechnol Bioeng. 2011 Oct;108(10):2456-67. doi: 10.1002/bit.23196. Epub 2011 May 12.

11.

B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors.

Kaifu T, Escalière B, Gastinel LN, Vivier E, Baratin M.

Cell Mol Life Sci. 2011 Nov;68(21):3531-9. doi: 10.1007/s00018-011-0802-7. Epub 2011 Aug 30. Review.

PMID:
21877119
12.

Coevolution of MHC genes (LMP/TAP/class Ia, NKT-class Ib, NKp30-B7H6): lessons from cold-blooded vertebrates.

Ohta Y, Flajnik MF.

Immunol Rev. 2015 Sep;267(1):6-15. doi: 10.1111/imr.12324. Review.

13.

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.

Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M.

J Immunol. 2012 Nov 15;189(10):5037-46. doi: 10.4049/jimmunol.1201321. Epub 2012 Oct 12.

14.

Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display.

Yu X, Qu L, Bigner DD, Chandramohan V.

Protein Eng Des Sel. 2017 Sep 1;30(9):639-647. doi: 10.1093/protein/gzx038.

15.

A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells.

Binici J, Hartmann J, Herrmann J, Schreiber C, Beyer S, Güler G, Vogel V, Tumulka F, Abele R, Mäntele W, Koch J.

J Biol Chem. 2013 Nov 29;288(48):34295-303. doi: 10.1074/jbc.M113.483602. Epub 2013 Oct 16.

16.

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.

Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ.

PLoS One. 2013;8(3):e57838. doi: 10.1371/journal.pone.0057838. Epub 2013 Mar 1.

17.

A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.

Prapa M, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, Petrachi T, Conte P, Horwitz EM, Campana D, Paolucci P, Dominici M.

Oncotarget. 2015 Sep 22;6(28):24884-94. doi: 10.18632/oncotarget.4670.

18.

Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.

Thueng-in K, Thanongsaksrikul J, Jittavisutthikul S, Seesuay W, Chulanetra M, Sakolvaree Y, Srimanote P, Chaicumpa W.

MAbs. 2014;6(5):1327-39. doi: 10.4161/mabs.29978.

19.

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.

Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W, Man-Yuen Sze D, Yi Q, Hou J.

Mol Oncol. 2014 Mar;8(2):297-310. doi: 10.1016/j.molonc.2013.12.001. Epub 2013 Dec 12.

20.

B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR, Sentman CL.

J Immunol. 2015 Jun 1;194(11):5305-11. doi: 10.4049/jimmunol.1402517. Epub 2015 Apr 24.

Supplemental Content

Support Center